Drug Trial Radar · NCT01301898
To Evaluate the Safety and Efficacy of GC1111 (Recombinant Human Iduronate-2-sulfatase) in Hunter Syndrome Patients
Last checked: Nov 20, 2026Latest source record: Feb 14, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
31
Actual
Start
May 2010
Primary completion
Mar 2011
Study completion Mar 2011
Sponsor
- Lead sponsor
- Green Cross CorporationIndustry
- Sponsor type
- Industry
- First posted
- Feb 23, 2011
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- Who can join
- Male only, from 6 years, up to 35 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of GC1111 (recombinant human iduronate-w-sulfatase) in Hunter Syndrome (Mucopolysaccharidosis II) patients
Conditions
- Mucopolysaccharidosis II
Interventions
GC1111_0.5mg/kgDrug
GC1111_1.0mg/kgDrug
Elaprase_0.5mg/kgDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary OutcomeTime frame: baseline, every 4 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Samsung Medical Center
Seoul, Irwon-dong, Gangnam-Gu, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.